Abstract
In this review, we focus specifically on the role that the metalloproteinase, A Disintegrin and Metalloproteinase 17 [ADAM17] plays in the development and progression of the metabolic syndrome. There is a well-recognised link between the ADAM17 substrate tumour necrosis factor α (TNF-α) and obesity, inflammation and diabetes. In addition, knocking out ADAM17 in mice leads to an extremely lean phenotype. Importantly, ADAM17-deficient mice exhibit one of the most pronounced examples of hypermetabolism in rodents to date. It is vital to further understand the mechanistic role that ADAM17 plays in the metabolic syndrome. Such studies will demonstrate that ADAM17 is a valuable therapeutic target to treat obesity and diabetes.
Highlights
There is increasing evidence showing the link between metabolic syndrome and cardiovascular disease, chronic kidney disease, stroke and diabetes [1]
One study has highlighted that when a disintegrin and metalloproteinase 17 (ADAM17) is activated within the white adipocytes, it leads to the expression of inflammatory molecules such as Interleukin 6 (IL-6), Monocyte Chemotactic Protein 1 (MCP-1) and Suppressor of Cytokine Signalling 3 (SOCS3) [30,34]
We believe that Sodium Glucose Co-transporter 2 (SGLT2) inhibition should be conducted in diabetic mice and ADAM17 expression and activity should be further studied in this animal model
Summary
Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes. We focus on the role that the metalloproteinase, A Disintegrin and Metalloproteinase 17 [ADAM17] plays in the development and progression of the metabolic syndrome. There is a well-recognised link between the ADAM17 substrate tumour necrosis factor α (TNF-α) and obesity, inflammation and diabetes. Knocking out ADAM17 in mice leads to an extremely lean phenotype. ADAM17-deficient mice exhibit one of the most pronounced examples of hypermetabolism in rodents to date. It is vital to further understand the mechanistic role that ADAM17 plays in the metabolic syndrome. Such studies will demonstrate that ADAM17 is a valuable therapeutic target to treat obesity and diabetes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
